Industry
Should investors be concerned about RNAZ’s high price-to-sales ratio?
TransCode Therapeutics Inc (RNAZ)’s stock is trading at $3.60 at the moment marking a fall of -42.97% from the last session close. As of this
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.